Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Collaboration › Details

Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202309–203309 supply 10y >$100m of nca lutetium-177 to Point Biopharma

 

Period Period 2023-09-25
Organisations Partner, 1st Point Biopharma Global Inc. (Nasdaq: PNT)
  Group Eli Lilly (Group)
  Partner, 2nd Eckert & Ziegler AG
  Today Eckert & Ziegler Strahlen- und Medizintechnik AG
  Group Eckert & Ziegler (Group)
Products Product lutetium-177 (medical isotope)
  Product 2 RADIOPHARMACEUTICAL (RPT)
     

Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin.

Insider information pursuant to Article 17 MAR


Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today signed an agreement with POINT Biopharma Global Inc. ("POINT", NASDAQ: PNT) for the supply of carrier-free lutetium-177 (n.c.a.177Lu). The agreement has a term of ten years with a total sales volume of more than € 100 million.

The lutetium-177 supply is conditional to successful validation of Eckert & Ziegler-produced lutetium-177 with the intended compounds. POINT’s pipeline has multiple lutetium-177-based clinical candidates including one candidate for the treatment of metastatic castration-resistant prostate cancer. The agreement’s projected sales volume is based on the successful regulatory approval of a lutetium-177-based clinical candidate in the future.

To expand its manufacturing capacities, Eckert & Ziegler plans to invest around € 10 million in its own site in Wilmington, MA. Eckert & Ziegler is thus positioning itself as an important supplier of lutetium-177 in the rapidly growing radioligand therapy market.

The strategically significant agreement is expected to start contributing revenues in 2023 and generate substantial earnings if POINT's clinical candidates receive regulatory approval.

The lutetium-177 supply agreement follows a previously signed actinium-225 supply agreement between Eckert & Ziegler and POINT, announced on April 4, 2023.


Contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com


End of Inside Information

   
Record changed: 2023-11-12

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Eli Lilly (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px




» top